...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>ClinicoEconomics and Outcomes Research >Effect of occasional epoetin use in combination with a stable darbepoetin dosage on anemia management in hemodialysis patients
【24h】

Effect of occasional epoetin use in combination with a stable darbepoetin dosage on anemia management in hemodialysis patients

机译：偶尔使用依泊汀与稳定的达贝泊汀剂量联合使用对血液透析患者贫血的控制

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Aim: Taking advantage of the characteristics of both darbepoetin (DA) and epoetin (EPO) might be a reasonable option for stabilizing hemoglobin (Hb) control in hemodialysis (HD) patients. The effect of DA assisted by EPO (DA/EPO) on Hb control was evaluated retrospectively in comparison with that of EPO monotherapy. Methods: Twenty-six HD patients whose annual mean Hb values were available for both an EPO monotherapy period and a DA/EPO period were selected for analysis. During the DA/EPO period, DA was given on the second HD day of a week, and EPO was given if needed on the first and third HD days. Under stable DA dosage, when Hb rose >12 g/dL, EPO was eliminated. When Hb decreased <10 g/dL, EPO was added again. The variability of annual mean Hb values from the 26 HD patients during the DA/EPO period was compared with that during the EPO period. Additionally, the distance in Hb (d-Hb; absolute value of difference) between the annual mean Hb values and the target Hb (11 g/dL) during the DA/EPO period was compared with that during the EPO period. Results: The variability of annual mean Hb values during the DA/EPO period was significantly smaller than that during the EPO period (11.2±0.25 g/dL versus [vs] 11.0±0.50 g/dL; the F -test for equality of variance, P <0.001). Additionally, the d-Hb during the DA/EPO period was significantly smaller than that during the EPO period (0.22±0.21 g/dL vs 0.38±0.31 g/dL, P <0.03). The total doses (as EPO equivalents) of DA with EPO were reduced to 82.2% of the baseline EPO dose during the EPO monotherapy period. The expenditure for the DA/EPO period was significantly reduced to 80.9% of that for the EPO monotherapy. Also, the annual total amount of intravenous iron supplementation during the DA/EPO period was significantly reduced compared with that during the EPO period (546±304 mg/year vs 684±314 mg/year, P <0.05). Conclusion: The occasional use of EPO in combination with a stable DA dosage may be useful for Hb control within a narrow range of the target level.
机译：目的：充分利用达比泊汀（DA）和依泊汀（EPO）的特性可能是稳定血液透析（HD）患者血红蛋白（Hb）控制的合理选择。与EPO单药治疗相比，回顾性评估了EPO辅助DA（DA / EPO）对Hb控制的效果。方法：选择26例HD患者，这些患者在EPO单药治疗和DA / EPO治疗期间均具有年平均Hb值。在DA / EPO期间，在一周的第二个高清日进行DA，如果需要，在高清的第一天和第三天进行EPO。在稳定的DA剂量下，当Hb升高> 12 g / dL时，EPO被消除。当Hb降低<10 g / dL时，再次添加EPO。比较了DA / EPO期间26例HD患者的年平均Hb值与EPO期间的年均Hb值的差异。此外，将DA / EPO期间的年平均Hb值与目标Hb（11 g / dL）之间的Hb距离（d-Hb;差的绝对值）与EPO期间的距离进行了比较。结果：DA / EPO期间的年平均Hb值的变异性显着小于EPO期间的（11.2±0.25 g / dL，而[vs] 11.0±0.50 g / dL;方差相等的F检验，P <0.001）。此外，DA / EPO期间的d-Hb明显小于EPO期间的d-Hb（0.22±0.21 g / dL与0.38±0.31 g / dL，P <0.03）。在EPO单药治疗期间，含EPO的DA的总剂量（以EPO当量计）降低至基线EPO剂量的82.2％。 DA / EPO期间的支出显着减少到EPO单药治疗的80.9％。此外，与EPO期间相比，DA / EPO期间的年度静脉补铁总量显着减少（546±304 mg /年vs 684±314 mg /年，P <0.05）。结论：偶尔使用EPO和稳定的DA剂量可能有助于在目标水平的狭窄范围内控制Hb。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号